thread-index: Ad1Fbt0hD9+wJTA/RYqS+9qhIRlfNQ== Thread-Topic: Dr. Amin Tamadon From: "http://gsia.sums.ac.ir/" Subject: Dr. Amin Tamadon Organization: Targan Management Systems, http://www.targan.ir MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_01A4_01DD4534.30FE48D0" Content-Location: https://gsia.sums.ac.ir/en/ps/menu/18911 Content-Class: urn:content-classes:message Importance: normal Priority: normal X-MimeOLE: Produced By Microsoft MimeOLE This is a multi-part message in MIME format. ------=_NextPart_000_01A4_01DD4534.30FE48D0 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 7bit Shiraz University of Medical Sciences - SUMS Code : 18911 Publish Date : Monday, June 15, 2020 Visit : 2130 Dr. Amin Tamadon Dr. Amin Tamadon Dr. Amin Tamadon Professor Regenerative Medicine School of Public Health, Dentistry, Pharmacy and Nursing Department of Natural Sciences West Kazakhstan Marat Ospanov Medical University Aktobe, Kazakhstan E-mail Address: amintamaddon@yahoo.com Phone: +7 (7132) 56-34-25 Address: Maresyev St, Aktobe 030012, Kazakhstan CV Biography Dr. Amin Tamadon earned his DVM from Shiraz University, Iran (2005) and a PhD in Veterinary Obstetrics and Reproductive Diseases from the same institution (2010). He pursued Postdoctoral fellowships at Seoul National University, South Korea (2015) and Fudan University, China (2017). Currently, Dr. Tamadon serves as the Professor and Principal Investigator of Regenerative Medicine at West-Kazakhstan Marat Ospanov Medical University and is the founder of PerciaVista R&D Co., specializing in stem cell therapy. Research Priorities: Our collaboration with Shiraz University of Medical Sciences (SUMS) focuses on advancing stem cell therapy, particularly mesenchymal stem cells (MSCs) and exosome therapy, for various diseases. We aim to exchange PhD and postdoc students, conduct collaborative projects, and potentially commercialize therapies. Stem Cell Research Focus: MSCs and Exosome Therapy MSCs, multipotent cells with immune-modulating properties, hold promise for regenerative medicine. Our priorities include developing MSC isolation protocols, studying their differentiation potential, and exploring their immunomodulatory effects. We also aim to investigate the therapeutic potential of MSC-derived exosomes, focusing on their isolation, characterization, and mechanisms of action in tissue repair and immunomodulation. We propose a student exchange program to enhance collaboration. Students will receive training in stem cell and exosome research, participate in joint projects, and benefit from mentorship and networking opportunities. Our joint projects will focus on disease modeling, clinical trials, and biomarker discovery. We aim to develop disease models, conduct preclinical and clinical trials, and identify biomarkers for monitoring treatment response. To translate our research into therapies, we plan to protect intellectual property, form industry partnerships, and support startup creation. This will ensure the commercial viability of MSC and exosome-based therapies. Previous Academic Collaborations with SUMS: * Publication of more than 70 articles with SUMS affiliation. * Performing more than 20 research projects. * Collaboration in establishment of 2 labs and 1 research center at SUMS. Number and Duration of Previous Visits to SUMS: None ------=_NextPart_000_01A4_01DD4534.30FE48D0 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: 8bit Shiraz University of Medical Sciences - SUMS
Shiraz University of Medical Sciences - SUMS
Code : 18911      Publish Date : Monday, June 15, 2020 Visit : 2130

Dr. Amin Tamadon

Dr. Amin Tamadon

 

Dr. Amin Tamadon

Professor

Regenerative Medicine

School of Public Health, Dentistry, Pharmacy and Nursing

Department of Natural Sciences

West Kazakhstan Marat Ospanov Medical University

Aktobe, Kazakhstan

 

E-mail Address: amintamaddon@yahoo.com

Phone: +7 (7132) 56-34-25

Address: Maresyev St, Aktobe 030012, Kazakhstan

 

CV

 

 

Biography

Dr. Amin Tamadon earned his DVM from Shiraz University, Iran (2005) and a PhD in Veterinary Obstetrics and Reproductive Diseases from the same institution (2010). He pursued Postdoctoral fellowships at Seoul National University, South Korea (2015) and Fudan University, China (2017). Currently, Dr. Tamadon serves as the Professor and Principal Investigator of Regenerative Medicine at West-Kazakhstan Marat Ospanov Medical University and is the founder of PerciaVista R&D Co., specializing in stem cell therapy.

 

Research Priorities:

Our collaboration with Shiraz University of Medical Sciences (SUMS) focuses on advancing stem cell therapy, particularly mesenchymal stem cells (MSCs) and exosome therapy, for various diseases. We aim to exchange PhD and postdoc students, conduct collaborative projects, and potentially commercialize therapies.

Stem Cell Research Focus: MSCs and Exosome Therapy

MSCs, multipotent cells with immune-modulating properties, hold promise for regenerative medicine. Our priorities include developing MSC isolation protocols, studying their differentiation potential, and exploring their immunomodulatory effects. We also aim to investigate the therapeutic potential of MSC-derived exosomes, focusing on their isolation, characterization, and mechanisms of action in tissue repair and immunomodulation.

We propose a student exchange program to enhance collaboration. Students will receive training in stem cell and exosome research, participate in joint projects, and benefit from mentorship and networking opportunities.

Our joint projects will focus on disease modeling, clinical trials, and biomarker discovery. We aim to develop disease models, conduct preclinical and clinical trials, and identify biomarkers for monitoring treatment response.

To translate our research into therapies, we plan to protect intellectual property, form industry partnerships, and support startup creation. This will ensure the commercial viability of MSC and exosome-based therapies.

 

Previous Academic Collaborations with SUMS:

  • Publication of more than 70 articles with SUMS affiliation.
  • Performing more than 20 research projects.
  • Collaboration in establishment of 2 labs and 1 research center at SUMS.

 

Number and Duration of Previous Visits to SUMS:

None

 


------=_NextPart_000_01A4_01DD4534.30FE48D0--